Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Pembrolizumab versus Ipilimumab in Advanced Melanoma
5.759
Zitationen
22
Autoren
2015
Jahr
Abstract
The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced melanoma. (Funded by Merck Sharp & Dohme; KEYNOTE-006 ClinicalTrials.gov number, NCT01866319.).
Ähnliche Arbeiten
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 · 30.895 Zit.
AJCC Cancer Staging Manual
2016 · 17.399 Zit.
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
2017 · 15.271 Zit.
The blockade of immune checkpoints in cancer immunotherapy
2012 · 13.510 Zit.
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
2012 · 12.496 Zit.
Autoren
- Caroline Robert
- Jacob Schachter
- Georgina V. Long
- Ana Arance
- Jean‐Jacques Grob
- Laurent Mortier
- Adil Daud
- Matteo S. Carlino
- Catriona M. McNeil
- Michal Lotem
- James Larkin
- Paul Lorigan
- Bart Neyns
- Christian U. Blank
- Omid Hamid
- Christine Mateus
- Ronnie Shapira‐Frommer
- Michele Kosh
- Haiyu Zhou
- Nageatte Ibrahim
- Scot Ebbinghaus
- Antoni Ribas
Institutionen
- Université Paris-Sud(FR)
- Sheba Medical Center(IL)
- Mater Hospital(GB)
- Target (United States)(US)
- Breast Cancer Research Foundation(US)
- Hôpital de la Timone(FR)
- Centre Hospitalier Universitaire de Lille(FR)
- University of California, San Francisco(US)
- Institut Gustave Roussy(FR)
- Melanoma Institute Australia(AU)
- Chris O’Brien Lifehouse(AU)
- Royal Prince Alfred Hospital(AU)
- Hadassah Medical Center(IL)
- University Medical Center(US)
- Royal Marsden Hospital(GB)
- The Christie NHS Foundation Trust(GB)
- University of Manchester(GB)
- Universitair Ziekenhuis Brussel(BE)
- The Netherlands Cancer Institute(NL)
- Angeles Clinic and Research Institute(US)
- Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
- University of California, Los Angeles(US)